SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SLNO (MC $24 M) Rare Disease in P3 a Potential Blockbuster
SLNO 2.935+1.6%12:24 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: BioHero9/14/2017 8:49:34 AM
   of 6
 
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN)
analystratings.com

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics Inc (NASDAQ: SLNO) and Alexion Pharmaceuticals (NASDAQ: ALXN) with bullish sentiments.

Soleno Therapeutics Inc (NASDAQ: SLNO)

Maxim Group analyst Gabrielle Zhou assigned a Buy rating to Soleno Therapeutics Inc (NASDAQ: SLNO) today and set a price target of $5. The company’s shares opened today at $0.62.

Zhou noted:

“Soleno today announced the issuance of a new patent (9,757,384) from the U.S. Patent and Trademark Office for the use of pharmaceutical formulations of diazoxide and diazaxide choline (Diazoxide Choline Controlled Release Tablet; DCCR) to reduce aggressive behaviors in patients with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).”
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext